Nuohong Huikang Biotechnology
GMP-grade cell culture reagents for biomedical research.
About Nuohong Huikang Biotechnology
Sperikon, also known as Nuohong Huikang Biotechnology, is a high-tech enterprise established in 2020 that focuses on the innovation and production of liquid reagents for cell biology. The company was co-founded by scholars with experience in cell biology and artificial intelligence. The Chairman is Yin Shigang and the General Manager is Wang Zhou. Sperikon aims to build an independent supply chain for the cell biology industry, challenging the market dominance of foreign brands in China's biomedical reagent sector. The company's business model centers on the research, development, production, and sales of reagents for the entire cell biology research process. Its clients include scientific research institutions, biopharmaceutical companies, cell therapy firms, and medical aesthetics organizations. Sperikon provides a "one-stop-shop" for everything from basic research reagents to clinical-grade application solutions. The product portfolio includes serum-free stem cell culture media, serum substitutes, matrix gels, organoid culture kits, and reagents for cell and gene therapy (CGT). These products cater to a wide range of applications, from scientific research to GMP-grade production. A key technological asset is the proprietary SP-EasyM AI intelligent formula research and development platform. This platform utilizes a multi-omics database and neural network algorithms to create an "intelligent mapping model" between culture medium formulas and cell states. This approach precisely predicts the nutritional needs of different cell types, which has been shown to increase new product development efficiency by over 50%. All products are manufactured under strict quality control, adhering to ISO 13485 and cGMP standards. Sperikon operates two main sites: a research and development center in the Deyang Sperikon Industrial Park and a production facility, including a recently announced culture medium powder production workshop in Huai'an. This dual-hub strategy enables the company to manage the entire chain from R&D to large-scale production and supply.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Drug Development, Stem Cells, Biotech and Pharma
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2026 | $14M | $55M | Zero2IPO · Empower Investment | ↗ |
Growth signals
Latest recorded traffic for Nuohong Huikang Biotechnology is 2.4K monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
IMG PharmaceuticalsPharmaceutical platform for regenerative and bioactive products. |
Tokyo, Japan | Operational | — | — | — |
Amnion FoundationHuman cells from birth tissues for research. |
Winston-Salem, United States | Operational | |||
MonitCellHuman adipose-derived stem cell and ECM biopharmaceuticals |
Seoul, South Korea | Operational | |||
| Calgary, Canada | Closed | ||||
PranaXRegenerative biologics harnessing stem cell-derived exosomes technology |
Houston, United States | Operational | |||
Cellular IntelligenceAI-native virtual cell-signaling model for regenerative medicine |
Boston, United States | Operational | |||
| JTJiuzhitang Maker (Beijing) Cell TechnologyStem cell pharmaceuticals and regenerative medicine products | Dongcheng District, China | Operational | |||
Beijing Zhongwei Medical TechnologyPharmaceutical-grade cell drug innovation and development services |
China | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Nuohong Huikang Biotechnology in its local ecosystem
The Nuohong Huikang Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Zero2IPO- EIEmpower Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nuohong Huikang Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nuohong Huikang Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







